{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:05:15Z","timestamp":1790730315281,"version":"4.1.0"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virus Research"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.virusres.2024.199507","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T09:13:53Z","timestamp":1734081233000},"page":"199507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Achieving chronic hepatitis B functional cure: Factors and potential mechanisms"],"prefix":"10.1016","volume":"351","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0202-7488","authenticated-orcid":false,"given":"Jiarui","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linxiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yandi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzhen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5084-6715","authenticated-orcid":false,"given":"Bo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.virusres.2024.199507_bib0001","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.cgh.2019.07.018","article-title":"Durability of spontaneous and treatment-related loss of hepatitis B s antigen","volume":"18","author":"Alawad","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"12","key":"10.1016\/j.virusres.2024.199507_bib0002","doi-asserted-by":"crossref","first-page":"e14899","DOI":"10.1111\/ijcp.14899","article-title":"Role of hepatosteatosis in HBsAg seroconversion in HBeAg-negative chronic hepatitis B patients","volume":"75","author":"Bacaks\u0131z","year":"2021","journal-title":"Int. J. Clin. Pract."},{"issue":"1","key":"10.1016\/j.virusres.2024.199507_bib0003","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jhep.2023.11.002","article-title":"Genomics on the road to functional cure of hepatitis B","volume":"80","author":"Balagopal","year":"2024","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.virusres.2024.199507_bib0004","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1053\/j.gastro.2012.07.014","article-title":"Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues","volume":"143","author":"Boni","year":"2012","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.virusres.2024.199507_bib0005","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/apt.16172","article-title":"Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss","volume":"53","author":"Brakenhoff","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.virusres.2024.199507_bib0006","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1097\/HEP.0000000000000658","article-title":"Rate and durability of the clearance of HBsAg in Alaska Native persons with long-term HBV infection: 1982-2019","volume":"79","author":"Bruden","year":"2024","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.virusres.2024.199507_bib0007","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1038\/ajg.2009.371","article-title":"Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients","volume":"104","author":"Buster","year":"2009","journal-title":"Am. J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.virusres.2024.199507_bib0008","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/hep.29213","article-title":"A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha","volume":"66","author":"Cao","year":"2017","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.virusres.2024.199507_bib0009","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031552","article-title":"Hepatitis B Flare in hepatitis B e antigen-negative patients: a complicated cascade of innate and adaptive immune responses","volume":"23","author":"Chang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.virusres.2024.199507_bib0010","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41598-017-00111-0","article-title":"Serum hepatitis B core-related antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B","volume":"7","author":"Chen","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.virusres.2024.199507_bib0011","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.cgh.2019.04.044","article-title":"Variants in STAT4 associated with cure of chronic HBV infection in HBeAg-positive patients treated with Pegylated interferon-alpha","volume":"18","author":"Chen","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.virusres.2024.199507_bib0012","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/hep.31282","article-title":"Functional comparison of interferon-\u03b1 subtypes reveals potent hepatitis B virus suppression by a concerted action of interferon-\u03b1 and interferon-\u03b3 signaling","volume":"73","author":"Chen","year":"2021","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.virusres.2024.199507_bib0013","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1111\/jvh.13613","article-title":"Effects of on-treatment ALT flares on serum HBsAg and HBV RNA in patients with chronic HBV infection","volume":"28","author":"Choi","year":"2021","journal-title":"J. Viral. Hepat."},{"issue":"9","key":"10.1016\/j.virusres.2024.199507_bib0014","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.cgh.2020.09.004","article-title":"Ultra-Long-term Follow-up of Interferon Alfa Treatment for HBeAg-Positive Chronic Hepatitis B Virus Infection","volume":"19","author":"Choi","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.virusres.2024.199507_bib0015","unstructured":"Collaborators, P.O., 2023. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. Lancet Gastroenterol. Hepatol. 8(10), 879\u2013907."},{"key":"10.1016\/j.virusres.2024.199507_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2021.100540","article-title":"Hepatitis B core related antigen in relation to intrahepatic and circulating viral markers, before and after combination therapy","volume":"26","author":"Erken","year":"2021","journal-title":"Ann. Hepatol."},{"issue":"10","key":"10.1016\/j.virusres.2024.199507_bib0017","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.4049\/jimmunol.1501362","article-title":"Polarization of Monocytic myeloid-derived suppressor cells by hepatitis b surface antigen is mediated via ERK\/IL-6\/STAT3 signaling feedback and restrains the activation of T cells in chronic hepatitis B virus infection","volume":"195","author":"Fang","year":"2015","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.virusres.2024.199507_bib0018","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/cid\/ciaa013","article-title":"Hepatitis B Virus RNA as early predictor for response to Pegylated interferon alpha in HBeAg-negative chronic hepatitis B","volume":"72","author":"Farag","year":"2021","journal-title":"Clin. Infect. Dis."},{"issue":"7","key":"10.1016\/j.virusres.2024.199507_bib0019","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/jvh.13283","article-title":"The efficacy of hepatitis B treatments in achieving HBsAg seroclearance: a systematic review and meta-analysis","volume":"27","author":"Fonseca","year":"2020","journal-title":"J. Viral. Hepat."},{"key":"10.1016\/j.virusres.2024.199507_bib0020","unstructured":"Foundation, C.D.C., https:\/\/cdafound.org\/polaris-countries-dashboard\/. Available on Mar 9, 2024."},{"issue":"1","key":"10.1016\/j.virusres.2024.199507_bib0021","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hep.32314","article-title":"Getting to HBV cure: the promising paths forward","volume":"76","author":"Fung","year":"2022","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.virusres.2024.199507_bib0022","first-page":"314","article-title":"Reduction in intrahepatic cccDNA and integration of HBV in chronic hepatitis B patients with a functional cure","volume":"11","author":"Gan","year":"2023","journal-title":"J. Clin. Transl. Hepatol."},{"issue":"1","key":"10.1016\/j.virusres.2024.199507_bib0023","article-title":"Prediction model for the clearance of hepatitis B surface antigen in patients with chronic hepatitis B before interferon therapy: a prospective case-control study","volume":"14","author":"Geng","year":"2024","journal-title":"Diagnostics. (Basel)"},{"issue":"5","key":"10.1016\/j.virusres.2024.199507_bib0024","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jhep.2023.06.002","article-title":"Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: report from the 2022 AASLD-EASL HBV-HDV treatment endpoints conference","volume":"79","author":"Ghany","year":"2023","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.virusres.2024.199507_bib0025","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jhep.2023.09.039","article-title":"Higher TP53BP2 expression is associated with HBsAg loss in peginterferon-\u03b1-treated patients with chronic hepatitis B","volume":"80","author":"Guan","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virusres.2024.199507_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1120300","article-title":"End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation","volume":"13","author":"Guo","year":"2023","journal-title":"Front. Cell Infect. Microbiol."},{"issue":"22","key":"10.1016\/j.virusres.2024.199507_bib0027","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1097\/CM9.0000000000002886","article-title":"Incidence and factors associated with hepatitis B surface antigen seroclearance in patients co-infected with HBV\/HIV during antiretroviral therapy in Guangdong, China","volume":"136","author":"He","year":"2023","journal-title":"Chin. Med. J. (Engl)"},{"issue":"10","key":"10.1016\/j.virusres.2024.199507_bib0028","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200840","article-title":"Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers","volume":"217","author":"Hehle","year":"2020","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.virusres.2024.199507_bib0029","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jhep.2021.04.041","article-title":"Understanding HBcrAg components improves the interpretation of clinical HBcrAg assay results","volume":"75","author":"Hong","year":"2021","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.virusres.2024.199507_bib0030","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01695-20","article-title":"Characterization of hepatitis B Precore\/Core-Related antigens","volume":"95","author":"Hong","year":"2021","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.virusres.2024.199507_bib0031","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/apt.15058","article-title":"Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk","volume":"49","author":"Hsu","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"11","key":"10.1016\/j.virusres.2024.199507_bib0032","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1093\/infdis\/jiab241","article-title":"Incidences and determinants of functional cure during Entecavir or Tenofovir Disoproxil Fumarate for chronic hepatitis B","volume":"224","author":"Hsu","year":"2021","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.virusres.2024.199507_bib0033","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jhep.2022.01.021","article-title":"End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB","volume":"77","author":"Huang","year":"2022","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.virusres.2024.199507_bib0034","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.cgh.2023.09.040","article-title":"Metabolic dysfunction-associated steatotic liver disease facilitates hepatitis B surface antigen Seroclearance and Seroconversion","volume":"22","author":"Huang","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.virusres.2024.199507_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008338","article-title":"Interferon-stimulated gene 20 (ISG20) selectively degrades N6-methyladenosine modified Hepatitis B Virus transcripts","volume":"16","author":"Imam","year":"2020","journal-title":"PLoS. Pathog."},{"issue":"4","key":"10.1016\/j.virusres.2024.199507_bib0036","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3350\/cmh.2022.0434","article-title":"Hepatitis B core-related antigen: a novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy","volume":"29","author":"Inoue","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"issue":"2","key":"10.1016\/j.virusres.2024.199507_bib0037","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B","volume":"68","author":"Jeng","year":"2018","journal-title":"Hepatology"},{"issue":"10381","key":"10.1016\/j.virusres.2024.199507_bib0038","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","article-title":"Hepatitis B","volume":"401","author":"Jeng","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.virusres.2024.199507_bib0039","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/HEP.0000000000000524","article-title":"Single-cell RNA sequencing reveals the immunoregulatory roles of PegIFN-\u03b1 in patients with chronic hepatitis B","volume":"79","author":"Jiang","year":"2024","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.virusres.2024.199507_bib0040","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2161254","article-title":"The potential effect of HBV vaccination on off-treatment HBsAg reversion after interferon-induced HBsAg clearance","volume":"19","author":"Jiang","year":"2023","journal-title":"Hum. Vaccin. ImmunOther"},{"key":"10.1016\/j.virusres.2024.199507_bib0041","doi-asserted-by":"crossref","DOI":"10.1007\/s12072-024-10648-8","article-title":"Predictors of HBsAg seroclearance in patients with chronic HBV infection treated with pegylated interferon-\u03b1: a systematic review and meta-analysis","author":"Jiang","year":"2024","journal-title":"Hepatol. Int."},{"issue":"1","key":"10.1016\/j.virusres.2024.199507_bib0042","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/hep.28278","article-title":"Antiviral therapy in management of chronic hepatitis B viral infection in children: a systematic review and meta-analysis","volume":"63","author":"Jonas","year":"2016","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.virusres.2024.199507_bib0043","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s00535-015-1153-1","article-title":"Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients","volume":"51","author":"Jung","year":"2016","journal-title":"J. Gastroenterol."},{"issue":"15","key":"10.1016\/j.virusres.2024.199507_bib0044","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s40265-020-01400-1","article-title":"Bulevirtide: first approval","volume":"80","author":"Kang","year":"2020","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.virusres.2024.199507_bib0045","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jhep.2016.12.024","article-title":"Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B","volume":"66","author":"Leboss\u00e9","year":"2017","journal-title":"J. Hepatol."},{"issue":"13","key":"10.1016\/j.virusres.2024.199507_bib0046","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1016\/j.cgh.2019.09.038","article-title":"Efficacy of Lenvervimab, a recombinant human immunoglobulin, in treatment of chronic hepatitis B virus infection","volume":"18","author":"Lee","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.virusres.2024.199507_bib0047","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/liv.14701","article-title":"Sustained off therapy response after peglyated interferon favours functional cure and no disease progression in chronic hepatitis B","volume":"41","author":"Lee","year":"2021","journal-title":"Liver. Int."},{"key":"10.1016\/j.virusres.2024.199507_bib0048","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1091786","article-title":"Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU\/ml treated with pegylated interferon","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.virusres.2024.199507_bib0049","first-page":"592","article-title":"Differential response of HBV envelope-specific CD4 + T cells is related to HBsAg loss after stopping nucleos(t)ide analogue therapy","volume":"78","author":"Li","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.virusres.2024.199507_bib0050","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/apt.16149","article-title":"Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg)","volume":"53","author":"Lim","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.virusres.2024.199507_bib0051","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1016\/j.cgh.2021.04.031","article-title":"Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide analogues for chronic hepatitis B: the SWAP RCT","volume":"20","author":"Lim","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.virusres.2024.199507_bib0052","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s12072-020-10099-x","article-title":"Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis","volume":"14","author":"Liu","year":"2020","journal-title":"Hepatol. Int."},{"issue":"6","key":"10.1016\/j.virusres.2024.199507_bib0053","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.cmi.2015.02.010","article-title":"Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D","volume":"21","author":"Maasoumy","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"issue":"19","key":"10.1016\/j.virusres.2024.199507_bib0054","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00444-21","article-title":"RNA helicase DDX17 inhibits hepatitis B virus replication by blocking viral Pregenomic RNA Encapsidation","volume":"95","author":"Mao","year":"2021","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.virusres.2024.199507_bib0055","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/hep.32792","article-title":"Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: a systematic review and meta-analysis","volume":"77","author":"Mao","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.virusres.2024.199507_bib0056","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of Tenofovir Disoproxil Fumarate and Peginterferon \u03b1-2a Increases loss of hepatitis b surface antigen in patients with chronic hepatitis B","volume":"150","author":"Marcellin","year":"2016","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.virusres.2024.199507_bib0057","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.jhep.2021.04.051","article-title":"Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load","volume":"75","author":"Meier","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virusres.2024.199507_bib0058","article-title":"Editorial: targeting the Immune System to Treat Hepatitis B Virus Infection","volume":"13","author":"Meng","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.virusres.2024.199507_bib0059","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jhep.2012.09.029","article-title":"Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B","volume":"58","author":"Micco","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virusres.2024.199507_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.coviro.2023.101360","article-title":"Hepatitis-B virus: replication cycle, targets, and antiviral approaches","volume":"63","author":"Nasser","year":"2023","journal-title":"Curr. Opin. Virol."},{"issue":"4","key":"10.1016\/j.virusres.2024.199507_bib0061","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jhep.2014.05.044","article-title":"Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial)","volume":"61","author":"Ning","year":"2014","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.virusres.2024.199507_bib0062","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/hep.32331","article-title":"Diverse facets of MDSC in different phases of chronic HBV infection: impact on HBV-specific T-cell response and homing","volume":"76","author":"Pal","year":"2022","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.virusres.2024.199507_bib0063","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1111\/apt.15226","article-title":"Myeloid-derived suppressor cells induce regulatory T cells in chronically HBV infected patients with high levels of hepatitis B surface antigen and persist after antiviral therapy","volume":"49","author":"Pal","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.virusres.2024.199507_bib0064","doi-asserted-by":"crossref","first-page":"405","DOI":"10.14218\/JCTH.2021.00142","article-title":"Clinical predictors of functional cure in children 1-6 Years-old with chronic hepatitis B","volume":"10","author":"Pan","year":"2022","journal-title":"J. Clin. Transl. Hepatol."},{"issue":"3","key":"10.1016\/j.virusres.2024.199507_bib0065","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/hep.32400","article-title":"Changes in serum hepatitis B surface and e antigen, interferon-inducible protein 10, and aminotransferase levels during combination therapy of immune-tolerant chronic hepatitis B","volume":"76","author":"Perrillo","year":"2022","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.virusres.2024.199507_bib0066","doi-asserted-by":"crossref","first-page":"287","DOI":"10.4049\/jimmunol.0902761","article-title":"CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions","volume":"184","author":"Phillips","year":"2010","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.virusres.2024.199507_bib0067","doi-asserted-by":"crossref","first-page":"15296","DOI":"10.1038\/s41598-018-33719-x","article-title":"HBV induces inhibitory FcRL receptor on B cells and dysregulates B cell-T follicular helper cell axis","volume":"8","author":"Poonia","year":"2018","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.virusres.2024.199507_bib0068","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1046\/j.1365-2893.2003.00437.x","article-title":"Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment","volume":"10","author":"Rokuhara","year":"2003","journal-title":"J. Viral. Hepat."},{"issue":"4","key":"10.1016\/j.virusres.2024.199507_bib0069","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/hep.29609","article-title":"Hepatitis B virus sensitivity to interferon-\u03b1 in hepatocytes is more associated with cellular interferon response than with viral genotype","volume":"67","author":"Shen","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.virusres.2024.199507_bib0070","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/jvh.13471","article-title":"Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: a meta-analysis","volume":"28","author":"Song","year":"2021","journal-title":"J. Viral. Hepat."},{"issue":"7","key":"10.1016\/j.virusres.2024.199507_bib0071","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/infdis\/jiv180","article-title":"Natural Killer cell characteristics in patients with chronic hepatitis B Virus (HBV) infection are associated with HBV surface antigen clearance after combination treatment with Pegylated Interferon Alfa-2a and Adefovir","volume":"212","author":"Stelma","year":"2015","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.virusres.2024.199507_bib0072","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.virusres.2024.199507_bib0073","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1053\/j.gastro.2018.01.034","article-title":"Hepatitis B virus does not interfere with innate immune responses in the human liver","volume":"154","author":"Suslov","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virusres.2024.199507_bib0074","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1257113","article-title":"Hepatitis B surface antigen reduction is associated with hepatitis B core-specific CD8(+) T cell quality","volume":"14","author":"Takahama","year":"2023","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.virusres.2024.199507_bib0075","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.virusres.2024.199507_bib0076","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2018.11.030","article-title":"Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients","volume":"70","author":"Testoni","year":"2019","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.virusres.2024.199507_bib0077","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jhep.2012.11.007","article-title":"Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B?","volume":"58","author":"Thimme","year":"2013","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.virusres.2024.199507_bib0078","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jhep.2020.04.013","article-title":"Hepatitis B surface antigen seroclearance: immune mechanisms, clinical impact, importance for drug development","volume":"73","author":"Tout","year":"2020","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.virusres.2024.199507_bib0079","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3350\/cmh.2023.0194","article-title":"Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation","volume":"30","author":"Tsai","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"issue":"5","key":"10.1016\/j.virusres.2024.199507_bib0080","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jhep.2022.12.018","article-title":"A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B","volume":"78","author":"van B\u00f6mmel","year":"2023","journal-title":"J. Hepatol."},{"issue":"8","key":"10.1016\/j.virusres.2024.199507_bib0081","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1053\/j.gastro.2018.03.021","article-title":"Dysregulated response of follicular helper T cells to hepatitis b surface antigen promotes HBV persistence in mice and associates with outcomes of patients","volume":"154","author":"Wang","year":"2018","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.virusres.2024.199507_bib0082","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jhep.2019.12.009","article-title":"Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication","volume":"72","author":"Wang","year":"2020","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.virusres.2024.199507_bib0083","first-page":"197","article-title":"An ideal hallmark closest to complete cure of chronic hepatitis B patients: high-sensitivity quantitative HBsAg Loss","volume":"11","author":"Wang","year":"2023","journal-title":"J. Clin. Transl. Hepatol."},{"issue":"1","key":"10.1016\/j.virusres.2024.199507_bib0084","doi-asserted-by":"crossref","DOI":"10.1016\/S0618-8278(19)30141-0","article-title":"GS-13-Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV\/HDV co-infection","volume":"70","author":"Wedemeyer","year":"2019","journal-title":"J. Hepatol."},{"issue":"13","key":"10.1016\/j.virusres.2024.199507_bib0085","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.3748\/wjg.v26.i13.1525","article-title":"Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen \u2264 1500 IU\/mL: an observational study","volume":"26","author":"Wu","year":"2020","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.virusres.2024.199507_bib0086","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/hep.28222","article-title":"Predictors of hepatitis B e antigen-negative hepatitis in chronic hepatitis B virus-infected patients from childhood to adulthood","volume":"63","author":"Wu","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.virusres.2024.199507_bib0087","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12967-024-05062-5","article-title":"Routine evaluation of HBV-specific T cell reactivity in chronic hepatitis B using a broad-spectrum T-cell epitope peptide library and ELISpot assay","volume":"22","author":"Wu","year":"2024","journal-title":"J. Transl. Med."},{"issue":"2","key":"10.1016\/j.virusres.2024.199507_bib0088","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.cgh.2019.04.020","article-title":"Durability of interferon-induced hepatitis B surface antigen Seroclearance","volume":"18","author":"Wu","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.virusres.2024.199507_bib0089","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jmii.2019.09.004","article-title":"Quantitative of serum hepatitis B core antibody is a potential predictor of recurrence after interferon-induced hepatitis B surface antigen clearance","volume":"54","author":"Wu","year":"2021","journal-title":"J. Microbiol. Immunol. Infect."},{"issue":"9","key":"10.1016\/j.virusres.2024.199507_bib0090","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1007\/s00535-021-01812-0","article-title":"HBeAg-positive patients with HBsAg \u2009<\u2009100 IU\/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation","volume":"56","author":"Xie","year":"2021","journal-title":"J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.virusres.2024.199507_bib0091","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1053\/j.gastro.2022.10.008","article-title":"Current best practice in hepatitis B management and understanding long-term prospects for cure","volume":"164","author":"Yardeni","year":"2023","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.virusres.2024.199507_bib0092","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.gastro.2018.10.027","article-title":"Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis","volume":"156","author":"Yeo","year":"2019","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.virusres.2024.199507_bib0093","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2023.2259003","article-title":"The presence of baseline HBsAb-Specific B cells can predict HBsAg or HBeAg seroconversion of chronic hepatitis B on treatment","volume":"12","author":"Yin","year":"2023","journal-title":"Emerg. Microbes. Infect."},{"issue":"3","key":"10.1016\/j.virusres.2024.199507_bib0094","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","article-title":"HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues","volume":"70","author":"Yip","year":"2019","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.virusres.2024.199507_bib0095","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jhep.2022.11.020","article-title":"Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss","volume":"78","author":"Yip","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virusres.2024.199507_bib0096","first-page":"S115","article-title":"Similar risk of hepatocellular carcinoma in non-cirrhotic patients who achieved HBsAg seroclearance before the age of 50 and the general population","volume":"17","author":"Yip","year":"2023","journal-title":"Hepatol. Int."},{"issue":"5","key":"10.1016\/j.virusres.2024.199507_bib0097","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/gutjnl-2023-330577","article-title":"Spatial transcriptomics reveals a low extent of transcriptionally active hepatitis B virus integration in patients with HBsAg loss","volume":"73","author":"Yu","year":"2024","journal-title":"GutGut"},{"issue":"1","key":"10.1016\/j.virusres.2024.199507_bib0098","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13148-020-00928-z","article-title":"IFN-\u03b1 confers epigenetic regulation of HBV cccDNA minichromosome by modulating GCN5-mediated succinylation of histone H3K79 to clear HBV cccDNA","volume":"12","author":"Yuan","year":"2020","journal-title":"Clin. Epigenetics."},{"issue":"5","key":"10.1016\/j.virusres.2024.199507_bib0099","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/jvh.13792","article-title":"Early clinical efficacy of pegylated interferon treatment in patients with different phases of chronic HBV infection: a real-world analysis","volume":"30","author":"Zhang","year":"2023","journal-title":"J. Viral. Hepat."},{"key":"10.1016\/j.virusres.2024.199507_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105782","article-title":"Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy","volume":"221","author":"Zhao","year":"2024","journal-title":"Antiviral Res."}],"container-title":["Virus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170224002004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170224002004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:29:13Z","timestamp":1777508953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168170224002004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":100,"alternative-id":["S0168170224002004"],"URL":"https:\/\/doi.org\/10.1016\/j.virusres.2024.199507","relation":{},"ISSN":["0168-1702"],"issn-type":[{"value":"0168-1702","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Achieving chronic hepatitis B functional cure: Factors and potential mechanisms","name":"articletitle","label":"Article Title"},{"value":"Virus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virusres.2024.199507","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"199507"}}